BioAtla, Inc.
BCAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $12 |
| Gross Profit | -$0 | -$1 | -$0 | -$12 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $14 | $12 | $12 |
| G&A Expenses | $0 | $5 | $5 | $5 |
| SG&A Expenses | $4 | $5 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | -$0 | -$12 |
| Operating Expenses | $14 | $18 | $17 | $5 |
| Operating Income | -$14 | -$19 | -$18 | -$16 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | -$0 | $2 | $1 |
| Pre-Tax Income | -$16 | -$19 | -$15 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$19 | -$15 | -$15 |
| % Margin | – | – | – | – |
| EPS | -0.27 | -0.32 | -0.26 | -0.3 |
| % Growth | 15.6% | -23.1% | 13.3% | – |
| EPS Diluted | -0.27 | -0.32 | -0.26 | -0.3 |
| Weighted Avg Shares Out | 59 | 59 | 58 | 50 |
| Weighted Avg Shares Out Dil | 59 | 59 | 58 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | -$19 | -$17 | -$16 |
| % Margin | – | – | – | – |